Pharma & Biotech Global Week in Review 1 May 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Tarceva (Erlotinib) – India: Delhi High Court Appellate Bench holds in favour of Cipla against Roche in Tarceva patent litigation; Roche fined for ‘material suppression’ (Spicy IP) (PatLit) (Patent Circle) (Spicy IP) (Patent Circle) (Patent Circle) (GenericsWeb)

Lovenox (Enoxaparin) – US: Supreme Court denies certiorari petition in Aventis Pharma v Amphastar and Teva concerning inequitable conduct (Orange Book Blog) (GenericsWeb) (IP Watchdog)

 
General

The Swine Flu outbreak: Cipla on a patent roll (Spicy IP)

Brazil: Biodiversity patent application easier in Brazil (RelatIP)

Mexico: Counterfeit vaccine warning as Swine Flu hits Mexico (IP tango)

US: FDA petition response cements Orange Book preface therapeutic equivalence clarification (FDA Law Blog)

US: So, what happens when the US decides it no longer wishes to subsidise the world? (IAM)

US: Johnson & Johnson – 5 year exclusivity period would kill incentives to innovate (Patent Docs)

US: CHI CEO on patent reform and follow-on biologics legislation (Patent Docs)

US: BIO urges Congress on patent reform: First, do no harm (Patent Baristas)

US: Pharmaceutical advertising: How to use a domain name to circumvent application of law (Domain Name / Nom De Domaine!)

 
Products

Alimta (Pemetrexed) – US: Eli Lilly files patent infringement suit over Barr’s ANDA to manufacture generic Alimta (Patent Docs)

Arthrotech (Diclofenac/Misoprostol) – US: Pfizer files patent infringement suit against Teva over generic Arthrotech ANDA (Patent Docs)

Enablex (Darifenacin hydrobromide) – US: Watson files ANDA to market generic Enablex prior to expiration of Novartis’ patent (GenericsWeb)

Flanax (Naproxen) – US: TTAB precedential no 17: TTAB dismisses Bayer FLANAX cancellation claims – no famous marks exception in US law: Bayer Consumer Care AG v Belmora LLC (TTABlog)

Hectorol (Doxercalciferol) – US: Bone Care International files patent infringement suit against Eagle Pharmaceuticals over generic Hectorol ANDA (Patent Docs)

Hepsera (Adefovir dipivoxil) – India: Pregrant opposition – Delhi Patent Office rejects Gilead’s patent application covering crystalline adefovir dipivoxil (Patent Circle)

Lovaza (Omega-3-acid ethyl esters) – US: Pronova BioPharma files patent infringement suit in response to Teva’s ANDA to manufacture generic Lovaza (Patent Docs) (GenericsWeb)

Lovenox (Enoxaparin) – US: Supreme Court denies certiorari petition in Aventis Pharma v Amphastar and Teva concerning inequitable conduct (Orange Book Blog) (GenericsWeb) (IP Watchdog)

Lunesta (Eszopiclone) – US: Sepracor files patent infringement suit against Alphapharm over generic Lunesta ANDA (Patent Docs)

Mucinex / Mucinex DM (Guaifenesin / Guaifenesin/Dextromethorphan) – US: Reckitt Benckiser files patent infringement suit against Watson over generic Mucinex and Mucinex DM ANDA (Patent Docs)

Pawsitive ID kit – OptiGen asserts four patents against defendants’ Pawsitive ID kit for testing Progressive Rod-Cone Disease in dogs: OptiGen, LLC v Texas A&M University System et al (Patent Docs)

Perflubutane – EU: Community Marketing Authorisation waiver based on ‘even SPC won’t be enough’ argument is rejected: Nycomed Danmark ApS v European Medicines Agency (The SPC Blog)

Plavix (Clopidogrel) – EU: Teva withdraws bid for generic Plavix in Europe (GenericsWeb)

Tamiflu (Oseltamivir) and Relenza (Zanamivir) – Korea: Ministry of Health and Welfare reportedly says it will grant compulsory license on Tamiflu or Relenza if supply runs short of demand (Korea IP Law Blog)

Tarceva (Erlotinib) – India: Delhi High Court Appellate Bench holds in favour of Cipla against Roche in Tarceva patent litigation; Roche fined for ‘material suppression’ (Spicy IP) (PatLit) (Patent Circle) (Spicy IP) (Patent Circle) (Patent Circle) (GenericsWeb)

Viagra (Sildenafil) – Canada: Federal Court of Appeal finds Viagra worth a try, but not obvious: Apotex v Pfizer Canada (International Law Office)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: